First Ever Biosimilar Approval in China: Trouble for Roche?
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
Address: Rongjing Dong Street, Beijing Economic and Technological Development Zone Zip: 100176
Tel: -111549.584415584
Web: http://www.biotechplc.com/
BioteQ Bio-Pharmaceutical Co., Ltd. was established in August 2000, China and Cuba in the field of biotechnology, the highest level, the largest investment cooperation projects, to research and development and production of the treatment of malignant tumors, the source resistance, monoclonal antibodies and vaccines undertake the major projects of the National High-Tech Research and Development Plan, the national high-tech industrialization demonstration project for the main direction.
100 Thai Biological Pharmaceutical has China’s first world-class antibodies humanized technology platform, represents a core technology of the international bio-pharmaceutical development and direction of the mainstream. The company designed and built the production line of China’s first fully automated large-scale mammalian cell culture, which is currently the largest, most comprehensive facilities, the most technologically advanced large-scale cell culture technology platform.
The Biological Pharmaceutical Baitai successfully developed China’s first personal humanized monoclonal antibody drug – Taixinsheng nimotuzumab the drug in April 2005 Biology I class drug certificate issued by the State Food and Drug Administration , fill our humanized monoclonal antibody drugs blank. The Taixinsheng ® can specifically target the tumor cells to targeted therapies in killing tumor cells without damaging normal tissue, and represent the latest developments in the direction of the field of cancer treatment. Clinical studies have shown that Taixinsheng ® single-agent or combined radiotherapy and chemotherapy for head and neck cancer, colorectal cancer, glioma, non-small cell lung cancer efficacy, significant side effects is low, with high clinical value.
Same time the Biological Pharmaceutical Baitai actively carry out international technical transformation, is committed to nurturing the capability of independent innovation, new drugs are being developed, including the EGF vaccine for the treatment of cancer, psoriasis and rheumatoid arthritis, a humanized anti-CD6 single anti for reversal of organ transplant rejection anti-CD3 mAb.
The Biological Pharmaceutical development Baitai target large modern biopharmaceutical company, to improve antibody drug research and development capabilities and production levels, to improve the health of the people for the purpose, internationalization, industrialization, standardization, the scale of the operation mode, is committed to the latest achievements of the development of biotechnology into the cause of the health of the 21st century, and continuous dedication to the community is the most advanced, most excellent antibody drugs, witnessed the rise of China’s life sciences and biomedicine with you!
Research and Development
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
See our Cookie Privacy Policy Here
